News
10-08-2010, 12:41 AM
Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer.
More... (http://www.news-medical.net/news/20101008/Data-on-Abiraterone-Phase-III-Clinical-Trial-for-castration-resistant-prostate-cancer-to-be-presented-at-ESMO-meeting.aspx)
More... (http://www.news-medical.net/news/20101008/Data-on-Abiraterone-Phase-III-Clinical-Trial-for-castration-resistant-prostate-cancer-to-be-presented-at-ESMO-meeting.aspx)